Using antifibrinolytics in the peripartum period-concern for a hypercoagulable effect?
Document Type
Journal Article
Publication Date
1-1-2017
Journal
Journal of Neonatal-Perinatal Medicine
Volume
10
Issue
1
DOI
10.3233/NPM-16139
Keywords
Antifibrinolytic therapy; maximum clot firmness; postpartum haemorrhage; thromboelastometry; tranexamic acid
Abstract
© 2017-IOS Press and the authors. INTRODUCTION: Although antifibrinolytic agents are used to prevent and treat hemorrhage, there are concerns about a potential increased risk for peripartum venous thromboembolism. We sought to determine the impact of tranexamic acid and ϵ-aminocaproic acid on in vitro clotting properties in pregnancy. METHODS: Blood samples were obtained from healthy pregnant, obese, and preeclamptic pregnant women (n=10 in each group) prior to delivery as well as from healthy non-pregnant controls (n=10). Maximum clot firmness (MCF) and clotting time (CT) were measured using rotation thromboelastometry in the presence of tranexamic acid (3, 30, or 300 μg/mL) or ϵ-aminocaproic acid (30, 300, or 3000 μg/mL). ANOVA and regression analyses were performed. RESULTS: Mean whole blood MCF was significantly higher in healthy pregnant vs. non-pregnant women (66.5 vs. 57.5mm, p<0.001). Among healthy pregnant women, there was no significant difference between mean MCF (whole blood alone, and with increasing tranexamic acid doses=66.5, 66.1, 66.4, 66.3mm, respectively; p=0.25) or mean CT (409, 412, 420, 424sec; p=0.30) after addition of tranexamic acid. Similar results were found using ϵ-aminocaproic acid. Preeclamptic women had a higher mean MCF after the addition of ϵ-aminocaproic acid and tranexamic acid (p=0.05 and p=0.04, respectively) compared to whole blood alone. CONCLUSIONS: Pregnancy is a hypercoagulable state, as reflected by an increased MCF compared to non-pregnant women. Addition of antifibrinolytic therapy in vitro does not appear to increase MCF or CT for non-pregnant, pregnant, and obese women. Whether antifibrinolytics are safe in preeclampsia may require further study.
APA Citation
Ahmadzia, H., Lockhart, E., Thomas, S., Welsby, I., Hoffman, M., James, A., Murtha, A., Swamy, G., & Grotegut, C. (2017). Using antifibrinolytics in the peripartum period-concern for a hypercoagulable effect?. Journal of Neonatal-Perinatal Medicine, 10 (1). http://dx.doi.org/10.3233/NPM-16139